跳至主要内容
临床试验/NCT01130311
NCT01130311已完成不适用

A Randomized, Placebo-Controlled, Double-Blinded, 250-Subject Clinical Trial of Vitamin D Replacement in Patients With Pulmonary Tuberculosis

Aga Khan University4 个研究点 分布在 1 个国家目标入组 259 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
259
试验地点
4
主要终点
To measure difference in Clinical RESPONSES between test and control groups after treatment with vitamin D

研究概览

简要总结

Tuberculosis is a global public health problem. One third of the world's population is infected with tuberculosis (TB) with almost 2 million deaths per year globally. According to the WHO, Pakistan ranks 8th amongst the 22 high TB burden countries, with an estimated prevalence is 263 cases /100,000 populations.

In spite of effective therapy for drug sensitive TB, treatment failure occurs frequently leading to concerns for the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) mycobacterial strains. Therefore in the recent years, interest has been generated regarding the role of adjuvant immunomodulating therapy for the treatment of TB.

WHO has classified tuberculosis by disease severity into 3 distinct categories; mild, moderate and severe according to clinical presentations and host factors. Severity of disease has been linked to mycobacterium genotypes and with host factors such as vitamin D deficiency

Vitamin D is a hormone produced by the body in response to sun exposure. Independent of it's effects on bone mineralization, vitamin D is recognized to have numerous immune modulating effects; some specific to mycobacterium tuberculosis. Therefore vitamin D may enhance the host immune responses against the pathogen. Vitamin D status can be accurately determined by measuring the serum levels of 25-(OH) D3. A recent systemic review and meta-analysis explored the association between low serum vitamin D and risk of active tuberculosis and concluded that patients with tuberculosis have lower serum levels of vitamin D than healthy controls when matched for sex, age, ethnicity, diet and geographical location.

Vitamin D deficiency is not a life threatening condition. It usually is unrecognized or can present with generalized 'aches and pains' due to osteomalacia. The recommended dose for treatment of vitamin D deficiency is 200,000 IU/ month or 50,000 IU/ week, both given for 2 months or until the serum vitamin D level is > 30 ng/ml. Bone mineral density changes are usually completed by 10 weeks of treatment.

The investigators hypothesize that by replacing vitamin D in patients with active pulmonary tuberculosis, the 'Time to Recovery' can be shortened.Our aims are to determine whether replacing patients with insufficient and deficient levels of vitamin D affects the clinical outcome of the disease.

详细描述

Tuberculosis Tuberculosis (TB) is a global emergency. In 2004, there were an estimated 8.9 million new cases and 1.7 million deaths due to the disease1. In Pakistan, pulmonary tuberculosis (TB) is a major public health problem. The population of Pakistan is 160,943,000 with an estimated prevalence of all cases of tuberculosis at 263/100,000, an incidence of smear positive pulmonary TB of 181/100,000, and a mortality of 34/100,0002.

The management of TB remains a complicated issue even with the availability of effective anti-tuberculous drugs. One important aspect of this issue has been the difficulty clinicians' face in measuring clinical response in these patients, especially in smear-negative pulmonary and extra-pulmonary disease. Christian et al 3. have recently developed and validated a simple clinical score for the evaluation of TB patients. The score is based on eleven clinical variables, which were obtained from the WHO clinical manual for TB. These included self-reported parameters (e.g., cough, hemoptysis, dyspnoea, chest pain and night sweats), and signs comprising of anemic conjunctivae, tachycardia, positive findings at lung auscultation, axillary temperature >37.0˚C, body mass index (BMI) and middle upper arm circumference (MUAC). Each variable contributes 1 point, except for BMI and MUAC which contribute 2 points each, giving a maximum score of 13. Using this, score patients can be divided into 3 severity classes, providing an easy tool for clinical follow up and prognosis.

Vitamin D Vitamin D is normally synthesized in the skin under the influence of sunlight or ingested, It is readily metabo-lized in the liver to form 25-hydroxyvitamin D (25(OH)D), the accepted measure of vitamin D status. 25(OH)D is then further metabolized by the 1 hydroxylase enzyme to its biologically active metabolite, 1 , 25 dihy-droxyvitamin D (1 ,25[OH]2D) 4,5 . Activated vitamin D circulates with a binding protein and enters the target cell to interact with its nuclear receptor. This complex then combines with the retinoic acid X receptor to form a heterodimer, which in turn interacts with the Vitamin D response element on the target gene. By increasing in-testinal calcium and phosphate absorption6, increasing renal calcium reabsorption, and enhancing PTH-mediated bone resorption (via its effect on RANKL), vitamin D has the net effect of increasing the serum cal-cium and phosphate concentrations. Additionally, the vitamin D receptor element is present on multiple genes, the vitamin D receptor in many organs, and 1-alpha hydroxylase activity occurs in extrarenal tissues7. These local tissue effects are responsible for the non-mineral-related effects of vitamin D; such as cell differentiation and proliferation and immune regulation8.

Vitamin D deficiency The two most common causes of vitamin D deficiency remains decreased intake of vitamin D containing food and reduced sun exposure. The major source of vitamin D is exposure to sunlight, anything that diminishes the transmission or penetration of solar UVB into the skin will affect the cutaneous synthesis of vitamin D3. Vita-min D deficiency can therefore occur in people who live without sun exposure (including those whose skin is constantly protected from the sun by protective clothing, indoor life styles and sunscreen use.). In addition, very few foods naturally contain vitamin D and foods that are fortified with with vitamin D are often inadequate to satisfy the vitamin D requirements. Serum levels of less than 20 ng/mL (50 nmol/L) of 25-OH vitamin D are a commonly accepted cutoff for vitamin D deficiency , whereas levels between 20 and 30 ng/mL (50 to 75 nmol/L), are considered insufficiency9,10.

Asymptomatic or minimally symptomatic vitamin D deficiency is increasingly being recognized around the world. In Pakistan, a number of small studies have identified a high prevalence of vitamin D deficiency in pa-tient populations that include those presenting with hip fractures, obstetric cases and those attending ambulatory care clinics. Risk factors include a history of poor nutrition, lack of exposure to sunlight, and a low socioeco-nomic status. Zuberi LM et al11 reported that 92% of outpatients presenting to the AKUH, were vitamin D defi-cient; 62% had severe, 24% moderate and 8% had mild deficiency. Almost half of all these patients (including those with severe deficiency) were asymptomatic. Two separate studies from our center involving healthy, as-ymptomatic volunteers have identified a high prevalence of vitamin D deficiency (unpublished data). Baig MA et al12, in a study on outpatients from two public hospitals in Karachi, identified that 92% patients were vitamin D deficient and that the most severe form of D deficiency was seen in patients with tuberculosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (≥16 years on 1st March 2009) Males and Nonpregnant females
  • Active Pulmonary Tuberculosis diagnosed by Sputum Smear positivity for Acid fast bacilli (AFB)
  • Diagnosis within one week of inclusion into study
  • Not already on antituberculous treatment
  • Not receiving vitamin D replacement or supplementation

排除标准

  • History of having been treated with antimycobacterial therapy for < 6 months or with < 4 first-line anti-tuberculous drugs
  • Extra- pulmonary TB
  • Immune suppressed; with HIV infection, hepatic, renal failure, malignancy, diabetes mellitus
  • Sarcoidosis, hyperparathyroidism
  • Already on or requiring corticosteroids, immunosuppressive agents, thiazide diuretics
  • Breast feeding or pregnant
  • Symptomatic cardiac disease
  • Seriously ill or moribund patients with advanced respiratory impairment (cor pulmonale, hypercapnia, respiratory acidosis, congestive cardiac failure)
  • Allergy/sensitivity to study drugs or their formulations.
  • Concomitant use of drugs known to interfere with vitamin D levels; phenytoin, phenobarbital, carbamazepine, theophylline
  • Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

研究组 & 干预措施

Cholecalciferol (Vitamin D)

Experimental

Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL

干预措施: Cholecalciferol (Drug)

SALINE, INTRAMUSCULAR INJECTION

Placebo Comparator

NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial

干预措施: Saline injection (Drug)

结局指标

主要结局

To measure difference in Clinical RESPONSES between test and control groups after treatment with vitamin D

时间窗: 12 weeks

次要结局

  • To assess the effects of vitamin D replacement on cytokine responses(12 weeks)

研究者

申办方类型
Other

研究点 (4)

Loading locations...

相似试验